EUCTR2017-002631-42-FI
Active, not recruiting
Phase 1
A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis
ConditionsRelapsing multiple sclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
DrugsMavenclad®
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Relapsing multiple sclerosis
- Sponsor
- Merck KGaA
- Enrollment
- 300
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female subjects \= 18 years old
- •Highly active RMS as defined by:
- •\-One relapse in the previous year and at least 1 T1 Gd\+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs)
- •\-Two or more relapses in the previous year, whether on DMD treatment or not
- •EDSS score \=5\.0
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 300
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab
- •Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for IgG and/or IgM
- •Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result
- •Currently receiving immunosuppressive or myelosuppressive therapy with, e.g., monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids
- •History of tuberculosis , presence of active tuberculosis, or latent tuberculosis
- •Evidence or suspect of PML in MRI
- •Active malignancy or history of malignancy
- •lymphocyte count not within normal limits of the local hospital lab before initiation of first treatment course
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Clinical Research Study for People with Relapsing Multiple SclerosisRelapsing multiple sclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-002631-42-HUMerck KGaA300
Active, not recruiting
Phase 1
A Clinical Research Study for People with Relapsing Multiple SclerosisEUCTR2017-002631-42-ATMerck KGaA265
Active, not recruiting
Phase 1
A Clinical Research Study for People with Relapsing Multiple SclerosisEUCTR2017-002631-42-SEMerck KGaA265
Active, not recruiting
Phase 1
A Clinical Research Study for People with Relapsing Multiple SclerosisEUCTR2017-002631-42-BEMerck KGaA300
Active, not recruiting
Phase 1
A Clinical Research Study for People with Relapsing Multiple SclerosisRelapsing multiple sclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-002631-42-GBMerck KGaA265